Several research firms recently commented on ADMS. Cowen and Company reiterated an “outperform” rating and set a $45.00 target price on shares of Adamas Pharmaceuticals in a research note on Sunday, May 28th. Mizuho reiterated a “buy” rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. BidaskClub cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. Finally, Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 3rd.
Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) have been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.50.
In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the business’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $17.05, for a total value of $5,967,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 731,041 shares of company stock worth $12,476,149 in the last three months. Insiders own 29.00% of the company’s stock.
Large investors have recently made changes to their positions in the stock. American International Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 682 shares during the period. Wells Fargo & Company MN raised its stake in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the last quarter. Trexquant Investment LP purchased a new stake in Adamas Pharmaceuticals during the first quarter valued at $287,000. Russell Investments Group Ltd. purchased a new stake in Adamas Pharmaceuticals during the fourth quarter valued at $469,000. Finally, Goldman Sachs Group Inc. raised its stake in Adamas Pharmaceuticals by 212.9% in the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after buying an additional 41,436 shares during the last quarter. 71.37% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Adamas Pharmaceuticals (NASDAQ ADMS) remained flat at $17.17 during mid-day trading on Monday. 124,770 shares of the company were exchanged. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $19.50. The firm has a 50-day moving average of $17.39 and a 200 day moving average of $16.84. The stock’s market capitalization is $383.90 million.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 45.19%. During the same quarter in the previous year, the company posted ($0.65) earnings per share. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.47) EPS for the current fiscal year.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.